The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia (abnormal growth or development leading to an alteration in size, shape, and organization of the cell) in one or more of the major myeloid cell lines (WBC, RBC, and/or platelets), ineffective hematopoiesis, and an increased risk of developing acute myelogenous leukemia (AML). MDS occurs primarily in older adults, with a median age of 70 years. The majority of recipients present with symptoms related to cytopenias. Most recipients present with anemia requiring RBC transfusions.

Primary or de novo MDS occurs without a known history of chemotherapy or radiation exposure. Some inherited hematologic disorders, such as Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and Diamond-Blackfan syndrome are associated with an increased risk of MDS.

Question 1: Date of diagnosis of primary disease for HCT / cellular therapy

Report the date of the first pathological diagnosis (e.g., bone marrow or tissue biopsy) of the disease. Enter the date the sample was collected for examination. If the diagnosis was determined at an outside center, and no documentation of a pathological or laboratory assessment is available, the dictated date of diagnosis within a physician note may be reported. Do not report the date symptoms first appeared.

If the recipient’s MDS progressed to from a lower grade MDS to a higher grade MDS, report the diagnosis date of the original MDS diagnosis (i.e., the lower MDS grade). The transformation date (i.e., diagnosis of the higher grade) is captured below.

If the recipient’s MDS transformed to AML prior to HCT, report the diagnosis date of AML and ensure the primary disease for infusion is reported as AML. Ensure AML section of the Disease Classification Form is completed appropriately. The MDS diagnosis date is captured below.

If the exact diagnosis date is not known, use the process described in General Instructions, Guidelines for Completing Forms

Question 195: What was the MDS subtype at diagnosis?

Please indicate the MDS subtype at diagnosis. For a list of MDS subtypes and their diagnostic criteria, see Appendix H.

Questions 196 – 197: Specify Myelodysplastic syndrome, unclassifiable (MDS-U)

Specify the Myelodysplastic syndrome, unclassifiable (MDS-U) and and indicate whether documentation was submitted to the CIBMTR (e.g., pathology report).

For further instructions on how to attach documents in FormsNet3 SM, refer to the Training Guide.

Question 198: Was the disease (MDS) therapy-related?

Agents such as radiation or systemic therapy used to treat other diseases (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, or breast cancer) can damage the marrow and lead to a secondary malignancy, such as MDS.

If the diagnosis of MDS is therapy-related, select Yes. If the diagnosis of MDS is not therapy-related, select No. If it is unknown if the MDS is therapy-related, select Unknown.

Do not report Yes if the recipient developed MDS after an environmental exposure (e.g., exposure to benzene).

Question 199: Did the recipient have a predisposing condition?

A predisposing condition contributes to the susceptibility of developing MDS. Therefore, diagnosis of the condition increases the likelihood that the recipient will develop MDS. If the recipient has a documented history of a predisposing condition, select Yes. If there is no history of a predisposing condition or if predisposition is unknown, indicate*No* or Unknown.

Questions 200 – 201: Specify condition

Specify the recipient’s predisposing condition.

  • Aplastic anemia may progress to MDS and/or AML. Aplastic anemia is a broad classification referring to bone marrow failure characterized by pancytopenia and marrow hypoplasia. If aplastic anemia is selected and the recipient is on the CRF track, the Aplastic Anemia Pre-HCT (2028) Form will come due.
  • DDX41-associated familial MDS is a rare germline heterozygous mutation. DDX41 represents a class of tumor suppressor genes in myeloid neoplasms.
  • Diamond-Blackfan anemia is a rare genetic disorder that affects the ability of the marrow from producing red blood cells. These recipients may present with anemia, recipients may also exhibit physical abnormalities such as: small head size, cleft lip, webbed neck, defects of the hands and a short stature. Fanconi anemia is a rare genetic blood disorder that prevents the body from producing a sufficient number of new blood cells to function properly. Abnormal blood cells may also be produced. These recipients are short in stature, exhibit skeletal abnormalities, and have an increased risk of developing solid tumors, MDS, and leukemias. If Fanconi anemia is selected and the recipient is on the CRF track, the Fanconi Anemia Pre-HCT (2029) Form will come due.
  • GATA2 deficiency is a rare genetic disorder which can cause a variety of issues including viral and bacterial infections, cytopenias, myelodysplasia, myeloid leukemias, pulmonary alveolar proteinosis and lymphedema
  • Li-Fraumeni syndrome is a rare genetic disorder which increases the risk of developing several types of cancers, notably: breast cancer, osteosarcoma, sarcoma, brain tumors and leukemias. Li-Fraumeni syndromes are associated with mutations in the TP53 gene.
  • Paroxysmal nocturnal hemoglobinuria (PNH) is a rare genetic disorder of the blood cells. The disease is characterized by destruction of red blood cells. blood clots and impaired bone marrow function. PNH is very closely related and often derives from aplastic anemia. If PNH is selected and the recipient is on the CRF track, the Aplastic Anemia Pre-HCT (2028) Form will come due
  • RUNX1 deficiency was previously known as “familial platelet disorder with propensity to myeloid malignancies”. Recipients with RUNX1 deficiencies typically present with mild to moderate thrombocytopenia with normal-sized platelets, functional platelets defects leading to prolonged bleeding and an increased risk to develop myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL).
  • SAMD9- or SAMD9L-associated familial MDS are germline mutations which can result in a spectrum of multisystem disorders that carry a markedly increased risk of developing myeloid malignancies.
  • Shwachman-Diamond syndrome (SDS) is a rare autosomal recessive disorder in which is characterized by exocrine pancreatic insufficiency, bone marrow dysfunction, and skeletal abnormalities.
  • Telomere biology disorder (including dyskeratosis congenita) are a complex set of inherited conditions defined by the presence of very short telomeres. Telomere biology disorder can be characterized by bone marrow failure and lung disease.

If the recipient had a predisposing condition not listed above, select Other condition and specify the condition.

A list of entities that would fall into the Other condition category include: ETV6-related familial thrombocytopenia, ANKRD26-related familial thrombocytopenia, SRP72-related familial aplastic anemia/MDS, MBD4-related familial leukemia, Bloom Syndrome, Noonan Syndrome, Neurofibromatosis, Downs Syndrome, ATG2B/GSKIP duplication (chromosome 14q32.2), MECOM-associated syndrome.

Question 202: Date CBC drawn

These questions are intended to capture the laboratory studies performed at the diagnosis of MDS. Testing may be performed multiple times around the time of diagnosis; report the most recent laboratory results performed prior to the start of first treatment of the primary disease for HCT. If the recipient’s MDS transformed, report the studies from the original diagnosis.

Report the date the sample was drawn

Question 203 – 204: WBC

Indicate whether the white blood cell (WBC) count was Known or Unknown at diagnosis. If Known, report the laboratory count and unit of measure documented on the laboratory report.

Question 205 – 206: Neutrophils

Indicate whether the neutrophil percentage in the blood was Known or Unknown at diagnosis. If Known, report the neutrophil percentage documented on the laboratory report.

Questions 207 – 208: Blasts in the blood

Indicate whether the percent blasts in the peripheral blood is Known or Unknown at diagnosis. If Known, report the laboratory value. If the percent blasts in blood at diagnosis is not known, report Unknown. Note, blasts are not typically seen in the peripheral blood. If blasts are NOT reported on the differential, Known and “0%” can still be reported.

Questions 209 – 210: Hemoglobin

Indicate whether the hemoglobin was Known or Unknown at diagnosis. If Known, report the laboratory count and unit of measure documented on the laboratory report.

Question 211: Were RBCs transfused ≤ 30 days before the date the CBC was drawn?

Transfusions temporarily increase the red blood cell count. It is important to distinguish between a recipient whose body is creating these cells and a recipient who requires transfusions to support the counts.

Indicate if red blood cells were transfused less than or equal to 30 days prior to the date the CBC was drawn as reported above.

Questions 212 – 213: Platelets

Indicate whether the platelet count was Known or Unknown at diagnosis. If Known, report the laboratory count and unit of measure documented on the laboratory report.

Question 214: Were platelets transfused ≤ 7 days before date the CBC was drawn?

Transfusions temporarily increase the platelet count. It is important to distinguish between a recipient whose body is creating the platelets and a recipient who requires transfusions to support the counts.

Indicate if platelets were transfused less than or equal to 7 days prior to the date the CBC was drawn as reported above.

Questions 215 – 216: Blasts in bone marrow

Indicate whether the percentage of blasts in the bone marrow was Known or Unknown at diagnosis. If Known, report the percentage documented on the laboratory report.

If multiple methods were used to detect the percentage of blasts in the bone marrow, the aspirate differential is the preferred method; followed by flow cytometry and IHC (immunohistochemical staining).

Question 217: Were cytogenetics tested (karyotyping or FISH)?

Cytogenetics is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of known chromosomal abnormalities that reflect the recipient’s disease. Testing methods include conventional chromosome analysis (karyotyping) or fluorescence in situ hybridization (FISH). For more information about cytogenetic testing and terminology, see Appendix C, Cytogenetic Assessments.

If no Indicate if cytogenetic studies were obtained at diagnosis. If cytogenetic studies were obtained, select Yes.

If cytogenetic studies were not obtained, or it is unknown if chromosome studies were performed, select No or Unknown, respectively.

Question 218: Were cytogenetics tested via FISH?

If FISH studies were performed at diagnosis, report Yes.

If FISH studies were not performed at diagnosis, FISH samples were inadequate, or it is unknown if performed, report No. See Appendix C, Cytogenetic Assessments, for assistance interpreting FISH results.

Report chromosomal microarrays / chromosomal genomic arrays as FISH assessments.

Question 219: Sample source

Indicate if the sample was from Bone marrow or from Blood. If multiple sources were used to test FISH at diagnosis, the preferred sample source is the bone marrow.

Question 220: Results of tests

If FISH assessments identified abnormalities, indicate Abnormalities identified.

If FISH assessments were unremarkable, indicate No abnormalities identified.

Questions 221 – 224: Specify cytogenetic abnormalities (FISH) at diagnosis

Report the International System for Human Cytogenetic Nomenclature (ISCN) compatible string.

Report the number of abnormalities detected by FISH at diagnosis. After indicating the number of abnormalities, select all abnormalities detected. If a clonal abnormality is detected, but not listed as an option, select Other abnormality, and specify the abnormality.

If multiple other abnormalities were detected, report “see attachment” and attach the final report(s) for any other abnormalities detected. For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 225: Was documentation submitted to the CIBMTR?

Indicate whether documentation was submitted to the CIBMTR (e.g., pathology report, FISH report). For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 226: Were cytogenetics tested via karyotyping?

If karyotyping was performed at diagnosis, report Yes. Report Yes even if there were no evaluable metaphase cells (these results will be specified below).

If karyotyping was not performed at diagnosis or it is unknown if performed, indicate No and continue.

Question 227: Sample source

Indicate if the sample was from Bone marrow or from Blood. If multiple sources were used for karyotyping assessments at diagnosis, the preferred sample source is the bone marrow.

Question 228: Results of test

If karyotyping assessments identified abnormalities, indicate Abnormalities identified.

If karyotyping assessments yielded No evaluable metaphases or there were No abnormalities identified, indicate as such.

Question 229 – 232: Specify cytogenetic abnormalities (karyotyping) identified at diagnosis

Report the International System for Human Cytogenetic Nomenclature (ISCN) compatible string, if applicable.

Report the number of abnormalities detected by karyotyping at diagnosis. After indicating the number of abnormalities, select all abnormalities detected. If a clonal abnormality is detected, but not listed as an option, select Other abnormality, and specify the abnormality.

If multiple other abnormalities were detected, report “see attachment” and attach the final report(s) for any other abnormalities detected. For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 233: Was documentation submitted to the CIBMTR?

Indicate whether documentation was submitted to the CIBMTR (e.g., FISH report, karyotype report). For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 234: Did the recipient progress or transform to a different MDS subtype or AML between diagnosis and the start of the preparative regimen / infusion?

Indicate if the recipient’s disease progressed to AML or transformed into a different MDS subtype between initial diagnosis and the start of the preparative regimen / infusion. Approximately one third of MDS cases transform into AML, signifying a poorer prognosis. Progression to AML is defined by an increase in blood or bone marrow blasts equal to or greater than 20%.

MDS subtypes may also transform / progress from one into another. A progression from one subtype of MDS to another indicates that the number of cytopenias, number of blasts, and/or morphology of marrow sufficiently qualified them for a higher grade (i.e., more severe) MDS. For example, an MDS classified as MDS-SLD at diagnosis whose blast count rises to 8% as documented on bone marrow aspirate would have progressed to MDS-EB-1.

Conversely, do not report a progression / transformation if the recipient’s assessments after diagnosis show that they qualify for a lower grade (i.e., less severe MDS). For example, a recipient who is diagnosed with MDS-EB-2, but whose assessments show that they meet the criteria for MDS-EB-1 as a response to treatment, would not qualify as a progression or transformation. In this example, the disease is lower grade (i.e., less severe), rather than a higher grade (i.e., more severe) so it should not be reported as a progression/transformation. See the table below for guidance in determining the severity of MDS progressions and transformations.

Grade of MDS Progression/Transformations

Lower Grade >>>>>> >>>>>> >>>>>> Higher Grade
MDS-SLD / MDS-RS-SLD / MDS-RS-MLD / Childhood MDS MDS-MLD MDS-EB-1 MDS-EB-2 AML
JMML/CMML AML

Indicate if the recipient’s disease progressed to AML or transformed from one MDS subtype to another. If the recipient’s disease transformed or progressed, select Yes. If there was no documented transformation or progression, select No.

Question 235: Specify the MDS subtype after transformation

Indicate the recipient’s current MDS subtype after transformation. If the recipient experienced more than one transformation after diagnosis, report the most recent subtype. For a list of MDS subtypes and their diagnostic criteria, see Appendix H.

If the recipient progressed or transformed to MDS unclassifiable, specify the MDS-U subtype. If the disease progressed to AML, continue with to report the date of MDS diagnosis. If MDS progresses to AML and the recipient is on the CRF track, the Acute Myelogenous Leukemia (AML) Pre-HCT (2010) Form will also come due.

For all other progressions or transformations, continue with to specify the date of the most recent transformation.

Question 226: Specify Myelodysplastic syndrome, unclassifiable (MDS-U)

The classification of myelodysplastic syndrome, unclassifiable (MDS-U) would be based off the bone marrow biopsy pathology report and can be reported as one of the following:

  • MDS-U with 1% blood blasts
  • MDS-U with single lineage dysplasia and pancytopenia
  • MDS-U based on defining cytogenetic abnormality

Specify the Myelodysplastic syndrome, unclassifiable (MDS-U) using the definitions listed.

Question 227: Specify the date of the most recent transformation:

Report the date of assessment that determined the most recent disease transformation (i.e., if there were multiple transformations, report the most recent). Report the date of the pathological evaluation (e.g., bone marrow) or blood/serum assessment (e.g., CBC, peripheral blood smear). Enter the date the sample was collected for pathological and laboratory evaluations.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

Question 228: Date of MDS Diagnosis

If the recipient’s MDS transformed to AML prior to HCT, report the date of diagnosis of MDS. If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

Ensure the date of diagnosis for AML has been reported as the diagnosis date, AML is reported as the primary disease for HCT, and the AML section of the Disease Classification Form has been complete appropriately. Go to the signature line.

Question 239: Date CBC drawn

Report the date the CBC was drawn at the last evaluation prior to the start of the preparative regimen / infusion. If multiple assessments were performed, report the most recent assessment prior to the start of the preparative regimen / infusion.

Questions 240 – 241: WBC

Indicate whether the white blood cell (WBC) count was Known or Unknown at the last evaluation prior to the start of the preparative regimen / infusion. If Known, report the laboratory count and unit of measure documented on the laboratory report.

Questions 242 – 243: Neutrophils

Indicate whether the neutrophil percentage in the blood was Known or Unknown at the last evaluation prior to the start of the preparative regimen / infusion. If Known, report the neutrophil percentage documented on the laboratory report.

Questions 244 – 245: Blasts in the blood

Indicate whether the percent blasts in the peripheral blood is Known or Unknown at the last evaluation prior to the start of the preparative regimen / infusion. If Known, report the laboratory value documented on the laboratory report. If the percent blasts in blood at last evaluation is not known, report Unknown. Note, blasts are not typically seen in the peripheral blood. If blasts are NOT reported on the differential, Known and “0%” can still be reported.

Questions 246 – 247: Hemoglobin

Indicate whether the hemoglobin was Known or Unknown at the last evaluation prior to the start of the preparative regimen / infusion. If Known, report the laboratory count and unit of measure documented on the laboratory report.

Question 248: Were RBCs transfused ≤ 30 days before the date the CBC was drawn?

Transfusions temporarily increase the red blood cell count. It is important to distinguish between a recipient whose body is creating these cells and a recipient who requires transfusions to support the counts.

Indicate if red blood cells were transfused less than or equal to 30 days prior to the date the CBC was drawn as reported above.

Questions 249 – 250: Platelets

Indicate whether the platelet count was Known or Unknown at the last evaluation prior to the start of the preparative regimen / infusion. If Known, report the laboratory count and unit of measure documented on the laboratory report.

Question 251: Were platelets transfused ≤ 7 days before the date the CBC was drawn?

Transfusions temporarily increase the platelet count. It is important to distinguish between a recipient whose body is creating the platelets and a recipient who requires transfusions to support the counts.

Indicate if platelets were transfused less than or equal to 7 days prior to the date the CBC was drawn as reported above.

Questions 252 – 253: Blasts in bone marrow

Indicate whether the percentage of blasts in the bone marrow was Known or Unknown at the last evaluation prior to the start of the preparative regimen / infusion. If Known, report the percentage documented on the pathology report.

If multiple assessments were performed at the last evaluation, report the most recent assessment prior to the start of the preparative regimen / infusion.

Question 254: Were cytogenetics tested (karyotyping or FISH)?

Cytogenetics is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of known chromosomal abnormalities that reflect the recipient’s disease. Testing methods include conventional chromosome analysis (karyotyping) or fluorescence in situ hybridization (FISH). For more information about cytogenetic testing and terminology, see Appendix C, Cytogenetic Assessments.

Indicate if cytogenetic studies were obtained at the last evaluation prior to the preparative regimen / infusion. If cytogenetic studies were obtained, select Yes.

If no cytogenetic studies were obtained, or it is unknown if chromosome studies were performed, select No or Unknown, respectively.

Question 255: Were cytogenetics tested via FISH?

Indicate if FISH studies were performed at the last evaluation prior to the start of the preparative regimen / infusion.

If FISH studies were not performed at the last evaluation prior to the start of the preparative regimen / infusion, FISH samples were inadequate, or it is unknown if performed, report No. See Appendix C, Cytogenetic Assessments, for assistance interpreting FISH results.

Report chromosomal microarrays / chromosomal genomic arrays as FISH assessments.

Question 256: Sample source

Indicate if the sample was from Bone marrow or from Blood. If FISH studies were performed on multiple samples at the last evaluation prior to the start of the preparative regimen / infusion, the bone marrow results are the preferred sample source to report.

Question 257: Results of tests

If FISH assessments identified abnormalities, indicate Abnormalities identified.

If FISH assessments were unremarkable, indicate No abnormalities identified.

Questions 258 – 261: Specify cytogenetic abnormalities (FISH) at last evaluation prior to the start of the preparative regimen / infusion

Report the International System for Human Cytogenetic Nomenclature (ISCN) compatible string, if applicable.

Report the number of abnormalities detected by FISH at the last evaluation prior to the preparative regimen / infusion. After indicating the number of abnormalities, select all abnormalities detected.

If a clonal abnormality is detected, but not listed as an option, select Other abnormality and specify the abnormality. If multiple other abnormalities were detected, report “see attachment” and attach the final report(s) for any other abnormalities detected. For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 262: Was documentation submitted to the CIBMTR?

Indicate whether documentation was submitted to the CIBMTR (e.g., FISH report). For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 263: Were cytogenetics tested via karyotyping?

If karyotyping was performed at the last evaluation prior to the preparative regimen / infusion, report Yes. Report Yes even if there were no evaluable metaphase cells (these results will be specified below).

If karyotyping was not performed at the last evaluation prior to the start of the preparative regimen / infusion or it is unknown, indicate No.

Question 264: Sample source

Indicate if the sample was from Bone marrow or from Blood. If karyotyping studies were performed on multiple samples at the last evaluation prior to the start of the preparative regimen / infusion, the bone marrow results are the preferred sample source to report

Question 265: Results of tests

If karyotyping assessments identified abnormalities, indicate Abnormalities identified.

If karyotyping assessments yielded No evaluable metaphases or there were* No abnormalities identified*, indicate as such.

Questions 266 – 269: Specify cytogenetic abnormalities (karyotyping) at last evaluation prior to the stat of the preparative regimen / infusion

Report the International System for Human Cytogenetic Nomenclature (ISCN) compatible string, if applicable.

Report the number of abnormalities detected by karyotyping prior to the start of the preparative regimen / infusion. After indicating the number of abnormalities, select all abnormalities detected.

If a clonal abnormality is detected, but not listed as an option, select Other abnormality and specify the abnormality. If multiple other abnormalities were detected, report “see attachment” and attach the final report(s) for any other abnormalities detected. For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 270: Was documentation submitted to the CIBMTR?

Indicate whether documentation was submitted to the CIBMTR (e.g., karyotype report). For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.

Question 271: What was the disease status?

Indicate the disease status of MDS at the last evaluation prior to the start of the preparative regimen / infusion.

Refer to the MDS Response Criteria section of the Forms Instructions Manual for definitions of each disease response.

Question 272: Specify the cell line examined to determine HI status

Indicate the cell line examined to determine hematologic improvement. To determine the cell line, review the Hematologic Improvement criteria listed in the MDS Response Criteria section of the Forms Instructions Manual.

If the cell lines examined to determine hematologic improvement included Hematologic Improvement – Erythroid (HI-E), continue with Specify transfusion dependence.

If the cell lines examined to determine hematologic improvement only included Hematologic Improvement – Platelets (HI-P) and/or Hematologic Improvement – Neutrophils (HI-N).

Question 273: Specify transfusion dependence

If the recipient’s pre-transplant disease status included Hematologic improvement – Erythroid (HI-E), indicate the transfusion dependence at the time of determining disease status at last evaluation prior to start of the preparative regimen / infusion.

Select Non-transfused (NTD) if the recipient was without RBC transfusions as supportive care for the disease within a period of 16 weeks prior to the start of the preparative regimen / infusion.

Select Low-transfusion burden (LTB) if the recipient had 3-7 RBC transfusions within a period of 16 weeks in at least 2 transfusion episodes with a maximum of 3 RBC transfusions in 8 weeks prior to the start of the preparative regimen / infusion.

Question 274: Date assessed

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen / infusion. The date reported should be that of the most disease-specific assessment within the pre-transplant work-up period (approximately 30 days). Clinical and hematologic assessments include pathological evaluation (e.g., bone marrow biopsy), radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), and laboratory assessment (e.g., CBC, peripheral blood smear), in addition to clinician evaluation and physical examination. Enter the date the sample was collected for pathological and laboratory evaluations; enter the date the imaging took place for radiographic assessments.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

Section Updates:

Question Number Date of Change Add/Remove/Modify Description Reasoning (If applicable)
. . . . .
Last modified: Sep 23, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.